First Time Loading...

10X Genomics Inc
NASDAQ:TXG

Watchlist Manager
10X Genomics Inc Logo
10X Genomics Inc
NASDAQ:TXG
Watchlist
Price: 26.51 USD -3.67%
Updated: Apr 25, 2024

Intrinsic Value

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. [ Read More ]

The intrinsic value of one TXG stock under the Base Case scenario is 25.25 USD. Compared to the current market price of 26.51 USD, 10X Genomics Inc is Overvalued by 5%.

Key Points:
TXG Intrinsic Value
Base Case
25.25 USD
Overvaluation 5%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
10X Genomics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TXG stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
10X Genomics Inc

Provide an overview of the primary business activities
of 10X Genomics Inc.

What unique competitive advantages
does 10X Genomics Inc hold over its rivals?

What risks and challenges
does 10X Genomics Inc face in the near future?

Has there been any significant insider trading activity
in 10X Genomics Inc recently?

Summarize the latest earnings call
of 10X Genomics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for 10X Genomics Inc.

Provide P/S
for 10X Genomics Inc.

Provide P/E
for 10X Genomics Inc.

Provide P/OCF
for 10X Genomics Inc.

Provide P/FCFE
for 10X Genomics Inc.

Provide P/B
for 10X Genomics Inc.

Provide EV/S
for 10X Genomics Inc.

Provide EV/GP
for 10X Genomics Inc.

Provide EV/EBITDA
for 10X Genomics Inc.

Provide EV/EBIT
for 10X Genomics Inc.

Provide EV/OCF
for 10X Genomics Inc.

Provide EV/FCFF
for 10X Genomics Inc.

Provide EV/IC
for 10X Genomics Inc.

Show me price targets
for 10X Genomics Inc made by professional analysts.

What are the Revenue projections
for 10X Genomics Inc?

How accurate were the past Revenue estimates
for 10X Genomics Inc?

What are the Net Income projections
for 10X Genomics Inc?

How accurate were the past Net Income estimates
for 10X Genomics Inc?

What are the EPS projections
for 10X Genomics Inc?

How accurate were the past EPS estimates
for 10X Genomics Inc?

What are the EBIT projections
for 10X Genomics Inc?

How accurate were the past EBIT estimates
for 10X Genomics Inc?

Compare the revenue forecasts
for 10X Genomics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of 10X Genomics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of 10X Genomics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of 10X Genomics Inc compared to its peers.

Compare the P/E ratios
of 10X Genomics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing 10X Genomics Inc with its peers.

Analyze the financial leverage
of 10X Genomics Inc compared to its main competitors.

Show all profitability ratios
for 10X Genomics Inc.

Provide ROE
for 10X Genomics Inc.

Provide ROA
for 10X Genomics Inc.

Provide ROIC
for 10X Genomics Inc.

Provide ROCE
for 10X Genomics Inc.

Provide Gross Margin
for 10X Genomics Inc.

Provide Operating Margin
for 10X Genomics Inc.

Provide Net Margin
for 10X Genomics Inc.

Provide FCF Margin
for 10X Genomics Inc.

Show all solvency ratios
for 10X Genomics Inc.

Provide D/E Ratio
for 10X Genomics Inc.

Provide D/A Ratio
for 10X Genomics Inc.

Provide Interest Coverage Ratio
for 10X Genomics Inc.

Provide Altman Z-Score Ratio
for 10X Genomics Inc.

Provide Quick Ratio
for 10X Genomics Inc.

Provide Current Ratio
for 10X Genomics Inc.

Provide Cash Ratio
for 10X Genomics Inc.

What is the historical Revenue growth
over the last 5 years for 10X Genomics Inc?

What is the historical Net Income growth
over the last 5 years for 10X Genomics Inc?

What is the current Free Cash Flow
of 10X Genomics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for 10X Genomics Inc.

Financials

Balance Sheet Decomposition
10X Genomics Inc

Current Assets 596m
Cash & Short-Term Investments 388.7m
Receivables 114.8m
Other Current Assets 92.5m
Non-Current Assets 369.1m
PP&E 344.9m
Intangibles 21.1m
Other Non-Current Assets 3.1m
Current Liabilities 127.2m
Accounts Payable 15.7m
Accrued Liabilities 80.7m
Other Current Liabilities 30.7m
Non-Current Liabilities 96.9m
Other Non-Current Liabilities 96.9m
Efficiency

Earnings Waterfall
10X Genomics Inc

Revenue
618.7m USD
Cost of Revenue
-209.4m USD
Gross Profit
409.3m USD
Operating Expenses
-665.2m USD
Operating Income
-255.9m USD
Other Expenses
830k USD
Net Income
-255.1m USD

Free Cash Flow Analysis
10X Genomics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

TXG Profitability Score
Profitability Due Diligence

10X Genomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

31/100
Profitability
Score

10X Genomics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

TXG Solvency Score
Solvency Due Diligence

10X Genomics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

10X Genomics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TXG Price Targets Summary
10X Genomics Inc

Wall Street analysts forecast TXG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TXG is 56.61 USD with a low forecast of 30.3 USD and a high forecast of 73.5 USD.

Lowest
Price Target
30.3 USD
14% Upside
Average
Price Target
56.61 USD
114% Upside
Highest
Price Target
73.5 USD
177% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TXG Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TXG Price
10X Genomics Inc

1M 1M
-27%
6M 6M
-28%
1Y 1Y
-48%
3Y 3Y
-87%
5Y 5Y
-32%
10Y 10Y
-32%
Annual Price Range
26.51
52w Low
26.51
52w High
62.98
Price Metrics
Average Annual Return 26.92%
Standard Deviation of Annual Returns 79.64%
Max Drawdown -88%
Shares Statistics
Market Capitalization 3.2B USD
Shares Outstanding 119 170 000
Percentage of Shares Shorted 10.16%

TXG Return Decomposition
Main factors of price return

What is price return decomposition?

TXG News

Other Videos

Company Profile

10X Genomics Inc Logo
10X Genomics Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

3.2B USD

Dividend Yield

0%

Description

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,239 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables, and software for analyzing biological systems. Its products include Chromium Single Cell Gene Expression, Single Cell Immune Profiling, Single Cell assay for transposase accessible chromatin (ATAC) + Gene Expression, Single Cell ATAC, Spatial Gene Expression, Spatial Gene Expression, Spatial Multiomics, and Targeted Gene Expression. Its instruments include Chromium X Series, Chromium Connect, and Chromium Controller. Its technology Next GEM technology, which include chips and compatible reagents, which are offered for single cell product portfolio. Its consumables portfolio includes microfluidic chips, slides, reagents, and other consumables for both its Visium and Chromium solutions. The firm's applications include clustered regularly interspaced short palindromic repeats (CRISPR) screening, multiomic cytometry, and immune receptor mapping.

Contact

CALIFORNIA
Pleasanton
6230 Stoneridge Mall Road
+19254017300.0
https://www.10xgenomics.com/

IPO

2019-09-12

Employees

1 239

Officers

Co-Founder, CEO & Director
Dr. Serge Saxonov Ph.D.
Co-Founder, President, Chief Scientific Officer & Director
Dr. Benjamin J. Hindson Ph.D.
Chief Financial Officer
Mr. Justin J. McAnear
Chief Legal Officer
Mr. Eric S. Whitaker Esq.
Founding Scientist & CTO
Mr. Michael Schnall-Levin
Manager of Investor Relations and Strategic Finance
Ms. Cassie Corneau
Show More
Chief People Officer
Ms. Rebecca Port
Director of Legal
Mr. James Bryant
Director of Product Management
Mr. Nikhil Rao
Senior Product Manager
Mr. Florian Baumgartner
Show Less

See Also

Discover More
What is the Intrinsic Value of one TXG stock?

The intrinsic value of one TXG stock under the Base Case scenario is 25.25 USD.

Is TXG stock undervalued or overvalued?

Compared to the current market price of 26.51 USD, 10X Genomics Inc is Overvalued by 5%.